Research Article
Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus
NPH Insulin during Pregnancy
Table 3
Maternal outcomes of pregnant women using insulin glargine versus NPH among the studies selected for meta-analysis.
| Maternal outcomes | Number of studies | Insulin glargine | NPH | Mean difference*/ odds ratio** | 95% confidence limits | Unadjusted mean/events | Number of patients | Unadjusted mean/events | Number of patients | Lower limit | Upper limit |
| Weight at delivery (kg) | 4 | 93.3 | 167 | 92.1 | 179 | −0.82* | −6.79 | 5.15 | Weight gain (kg) | 5 | 15.1 | 230 | 15 | 265 | 0.16* | −1.03 | 1.35 | HbA1c—1st trimester (%) | 4 | 7.67 | 143 | 7.65 | 158 | −0.08* | −0.64 | 0.49 | HbA1c—3rd trimester (%) | 6 | 6.7 | 252 | 6.8 | 286 | −0.01* | −0.07 | 0.05 | Severe hypoglycemia (n) | 4 | 9 | 155 | 20 | 205 | 0.84** | 0.18 | 3.79 | Pre-eclampsia (n) | 8 | 26 | 331 | 40 | 371 | 0.55** | 0.23 | 1.32 | Cesarean section (n) | 6 | 199 | 284 | 231 | 324 | 1.04** | 0.72 | 1.52 | Gestational hypertension (n) | 4 | 9 | 155 | 23 | 205 | 0.49** | 0.20 | 1.20 |
|
|
*Mean difference: insulin glargine versus NPH insulin; **Odds ratio: insulin glargine/NPH insulin.
|